Mega Lifesciences Public : Interim dividend payment 2022
August 11, 2022 at 06:54 am EDT
Share
Headline:
Interim dividend payment 2022
Security Symbol:
MEGA
Announcement Details
Dividend payment / Omitted dividend payment
Subject
Cash dividend payment
Date of Board resolution
11-Aug-2022
Type of dividend payment
Cash dividend payment
Record date for the right to receive dividends
25-Aug-2022
Ex-dividend date
24-Aug-2022
Payment for
Common shareholders
Cash dividend payment (baht per share)
0.75
Derived from profit under non-BOI privilege (baht per share)
0.15
Derived from profit under BOI privilege (baht per share)
0.60
Par value (baht)
0.50
Payment date
09-Sep-2022
Paid from
Operating period from 01-Jan-2022 to
30-Jun-2022 and Retained Earnings
The company hereby certifies that the information above is correct and complete.
Signature _________________
Signature _________________
(Mr.Vivek Dhawan)
(Mr.Thomas Abraham)
Director
Director
Authorized Persons to Disclose
Authorized Persons to Disclose
Information
Information
Remark
Interim dividend payment 2022
This announcement was prepared and disseminated by listed company or issuer through the electronic system which is provided for the purpose of dissemination of the information and related documents of listed company or issuer to the Stock Exchange of Thailand only. The Stock Exchange of Thailand has no responsibility for the correctness and completeness of any statements, figures, reports or opinions contained in this announcement, and has no liability for any losses and damages in any cases. In case you have any inquiries or clarification regarding this announcement, please directly contact listed company or issuer who made this announcement.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Mega Lifesciences pcl published this content on 11 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2022 10:53:18 UTC.
Mega Lifesciences Public Company Limited is engaged in manufacturing, marketing, selling and distributing quality pharmaceutical, nutraceutical products and Fast-Moving Consumer Goods (FMCG). Its segments include Maxxcare distribution business, Mega We Care branded products business, and original equipment manufacturer (OEM) business. The Maxxcare distribution business markets, sells and distributes various branded prescription pharmaceutical products, OTC and FMCG products. Its services include warehouse management, collections, including assuming the liability for bad debts, and value-added services. Its Mega We Care branded products business develops, manufactures, markets and sells its own brand of nutraceutical products, prescription pharmaceutical products and OTC products. Mega We Care branded products are sold in a total of 35 countries around the world. Its manufacturing facilities in Thailand and Australia accept various production orders from third-party customers.